269 related articles for article (PubMed ID: 19450703)
21. Metabolism and pharmacokinetics of a potent N-acylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) in rats and monkeys.
Reddy CN; Alhamza H; Chourey S; Ye Q; Gore V; Cossette C; Gravel S; Slobodchikova I; Vuckovic D; Rokach J; Powell WS
Eur J Pharm Sci; 2018 Mar; 115():88-99. PubMed ID: 29339225
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and Metabolism of Selective Oxoeicosanoid (OXE) Receptor Antagonists and Their Effects on 5-Oxo-6,8,11,14-eicosatetraenoic Acid (5-Oxo-ETE)-Induced Granulocyte Activation in Monkeys.
Cossette C; Chourey S; Ye Q; Nagendra Reddy C; Gore V; Gravel S; Slobodchikova I; Vuckovic D; Rokach J; Powell WS
J Med Chem; 2016 Nov; 59(22):10127-10146. PubMed ID: 27766872
[TBL] [Abstract][Full Text] [Related]
23. Oxidative stress-induced changes in pyridine nucleotides and chemoattractant 5-lipoxygenase products in aging neutrophils.
Graham FD; Erlemann KR; Gravel S; Rokach J; Powell WS
Free Radic Biol Med; 2009 Jul; 47(1):62-71. PubMed ID: 19376220
[TBL] [Abstract][Full Text] [Related]
24. Oxoeicosanoid receptor inhibition alleviates acute myocardial infarction through activation of BCAT1.
Lai Q; Yuan G; Shen L; Zhang L; Fu F; Liu Z; Zhang Y; Kou J; Liu S; Yu B; Li F
Basic Res Cardiol; 2021 Jan; 116(1):3. PubMed ID: 33484341
[TBL] [Abstract][Full Text] [Related]
25. Structural requirements for activation of the 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity.
Patel P; Cossette C; Anumolu JR; Gravel S; Lesimple A; Mamer OA; Rokach J; Powell WS
J Pharmacol Exp Ther; 2008 May; 325(2):698-707. PubMed ID: 18292294
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of 5-oxo-6,8,11,14-eicosatetraenoic acid-induced activation of neutrophils and eosinophils by novel indole OXE receptor antagonists.
Gore V; Gravel S; Cossette C; Patel P; Chourey S; Ye Q; Rokach J; Powell WS
J Med Chem; 2014 Jan; 57(2):364-77. PubMed ID: 24351031
[TBL] [Abstract][Full Text] [Related]
27. Novel Highly Potent and Metabolically Resistant Oxoeicosanoid (OXE) Receptor Antagonists That Block the Actions of the Granulocyte Chemoattractant 5-Oxo-6,8,11,14-Eicosatetraenoic Acid (5-oxo-ETE).
Chourey S; Ye Q; Reddy CN; Wang R; Cossette C; Gravel S; Slobodchikova I; Vuckovic D; Rokach J; Powell WS
J Med Chem; 2018 Jul; 61(14):5934-5948. PubMed ID: 29972644
[TBL] [Abstract][Full Text] [Related]
28. 5-Oxo-ETE analogs and the proliferation of cancer cells.
O'Flaherty JT; Rogers LC; Paumi CM; Hantgan RR; Thomas LR; Clay CE; High K; Chen YQ; Willingham MC; Smitherman PK; Kute TE; Rao A; Cramer SD; Morrow CS
Biochim Biophys Acta; 2005 Oct; 1736(3):228-36. PubMed ID: 16154383
[TBL] [Abstract][Full Text] [Related]
29. 5-oxo-ETE is a major oxidative stress-induced arachidonate metabolite in B lymphocytes.
Grant GE; Gravel S; Guay J; Patel P; Mazer BD; Rokach J; Powell WS
Free Radic Biol Med; 2011 May; 50(10):1297-304. PubMed ID: 21334434
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of 5-oxo-6,8,11,14-eicosatetraenoic acid by human monocytes and lymphocytes.
Zhang Y; Styhler A; Powell WS
J Leukoc Biol; 1996 Jun; 59(6):847-54. PubMed ID: 8691070
[TBL] [Abstract][Full Text] [Related]
31. Biological inactivation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human platelets.
Powell WS; Gravel S; Khanapure SP; Rokach J
Blood; 1999 Feb; 93(3):1086-96. PubMed ID: 9920859
[TBL] [Abstract][Full Text] [Related]
32. Phorbol myristate acetate stimulates the formation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human neutrophils by activating NADPH oxidase.
Powell WS; Gravelle F; Gravel S
J Biol Chem; 1994 Oct; 269(41):25373-80. PubMed ID: 7929234
[TBL] [Abstract][Full Text] [Related]
33. 5-oxo-6,8,11,14-eicosatetraenoic acid induces the infiltration of granulocytes into human skin.
Muro S; Hamid Q; Olivenstein R; Taha R; Rokach J; Powell WS
J Allergy Clin Immunol; 2003 Oct; 112(4):768-74. PubMed ID: 14564360
[TBL] [Abstract][Full Text] [Related]
34. The OXE receptor: a new therapeutic approach for asthma?
Jones CE
Trends Mol Med; 2005 Jun; 11(6):266-70. PubMed ID: 15949767
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, biological effects and pathophysiological implications of the novel arachidonic acid metabolite 5-oxo-eicosatetraenoic acid (Review).
Zimpfer U; Hofmann C; Dichmann S; Schopf E; Norgauer J
Int J Mol Med; 1998 Aug; 2(2):149-153. PubMed ID: 9855681
[TBL] [Abstract][Full Text] [Related]
36. 5-oxo-ETE activates migration of H295R adrenocortical cells via MAPK and PKC pathways.
Neuman I; Cooke M; Lemiña NA; Kazanietz MG; Cornejo Maciel F
Prostaglandins Other Lipid Mediat; 2019 Oct; 144():106346. PubMed ID: 31301403
[TBL] [Abstract][Full Text] [Related]
37. Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils.
Jones CE; Holden S; Tenaillon L; Bhatia U; Seuwen K; Tranter P; Turner J; Kettle R; Bouhelal R; Charlton S; Nirmala NR; Jarai G; Finan P
Mol Pharmacol; 2003 Mar; 63(3):471-7. PubMed ID: 12606753
[TBL] [Abstract][Full Text] [Related]
38. 5-Oxo-ETE receptor antagonists.
Gore V; Patel P; Chang CT; Sivendran S; Kang N; Ouedraogo YP; Gravel S; Powell WS; Rokach J
J Med Chem; 2013 May; 56(9):3725-32. PubMed ID: 23581530
[TBL] [Abstract][Full Text] [Related]
39. Targeting the OXE receptor with a selective antagonist inhibits allergen-induced pulmonary inflammation in non-human primates.
Cossette C; Miller LA; Ye Q; Chourey S; Reddy CN; Rokach J; Powell WS
Br J Pharmacol; 2022 Jan; 179(2):322-336. PubMed ID: 34766334
[TBL] [Abstract][Full Text] [Related]
40. Stimulating properties of 5-oxo-eicosanoids for human monocytes: synergism with monocyte chemotactic protein-1 and -3.
Sozzani S; Zhou D; Locati M; Bernasconi S; Luini W; Mantovani A; O'Flaherty JT
J Immunol; 1996 Nov; 157(10):4664-71. PubMed ID: 8906847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
